BioSpace News Archive

InterShunt Technologies, Inc., an early-stage medical device company developing a novel catheter-based solution to reduce left atrial pressure in heart failure patients, announced the completion of an equity financing.

PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of fully human antibody therapeutics, announced today that the company has entered into a research collaboration agreement with LegoChem Biosciences Inc. (KOSDAQ: 141080ks),

Valo Health LLC (Valo), the technology company working to transform the drug discovery and development process and accelerate the creation of life-changing drugs, closed a $190 million Series B financing and unveiled select therapeutic programs.

The U.S. Food and Drug Administration (FDA) has accepted a supplemental New Drug Application (sNDA) for Jardiance® (empagliflozin) which is being investigated as a potential new treatment to reduce the risk of cardiovascular death and hospitalization for heart failure

Perrigo Company plc, a leading provider of Quality, Affordable Self-Care Products, announced a formal partnership with Michigan State University, connecting the university’s clinical and research expertise with Perrigo’s product innovation, manufacturing scale and retail partnerships to empower consumers to take control of their self-care needs.

-- Becker Hewes, M.D., promoted to Chief Medical Officer -- -- Andy Boral, M.D., Ph.D., to transition from Chief Medical Officer to Executive Vice President, Clinical Development -- -- Marion Dorsch, Ph.D., Chief Scientific Officer, to depart the company

Receptor Life Sciences (RLS) today announced the completion of a pre-investigational new drug (preIND) meeting with the U.S. Food and Drug Administration (FDA).

Aviceda has assembled a renowned team of scientific entrepreneurs and biopharma senior executives to spearhead ongoing development efforts of pipeline candidates and help the company continue to explore growth opportunities.

Heat Biologics, Inc., a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, including multiple oncology product candidates and a novel COVID-19 vaccine, announces it has appointed William Ostrander as its Chief Financial Officer, effective January 4, 2021.

Jupiter Orphan Therapeutics, Inc. (“JOT”) a biotechnology company pioneering a novel and disease modifying product named JOTROL™, today announced that the first patient has been dosed in a Phase I dose escalation study of JOTROL™